Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $17.80 Average Target Price from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received a consensus rating of “Buy” from the four ratings firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $17.00.

A number of research firms recently commented on ARTV. HC Wainwright raised Artiva Biotherapeutics to a “buy” rating and set a $12.00 price target for the company in a research report on Wednesday, June 11th. Needham & Company LLC reduced their target price on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 15th.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in shares of Artiva Biotherapeutics by 250.7% during the 4th quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company’s stock worth $379,000 after purchasing an additional 26,893 shares during the period. Geode Capital Management LLC increased its holdings in Artiva Biotherapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after buying an additional 6,828 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after buying an additional 3,361 shares during the last quarter. Barclays PLC raised its position in Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after acquiring an additional 4,545 shares during the period. Finally, Northern Trust Corp boosted its stake in Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after acquiring an additional 4,335 shares during the last quarter.

Artiva Biotherapeutics Stock Up 1.1%

Shares of NASDAQ ARTV opened at $2.70 on Tuesday. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $17.31. The firm’s 50-day simple moving average is $2.24 and its 200 day simple moving average is $2.91.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.03). Sell-side analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.